Towards Healthcare
Hemophilia Market Size Expects to Project USD 27.27 Bn by 2034

Hemophilia Market Trends, Personalized Medicine and Precision Therapies

According to market projections, the hemophilia sector is expected to grow from USD 14.34 billion in 2024 to USD 27.27 billion by 2034, reflecting a CAGR of 6.64%. Hemophilia affects over 1.1M globally, often undiagnosed. Advances like gene therapy and long-acting treatments are reshaping care. In 2024, North America led the market share by 50%, while Europe grows fast. Hemophilia A, prophylaxis, and factor therapy dominate, with cures and gene therapy rising fast.

Content

  • Insight Code: 5534
  • No. of Pages: 400
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

Although there is not a definitive cure for hemophilia at this time, new treatments like gene therapy provide patients who have the condition hope for long-term care and maybe a more normal life.

Hympavzi is a novel kind of medication that functions by decreasing the quantity and, consequently, the activity of the naturally occurring anticoagulant protein known as tissue factor pathway inhibitor, as opposed to substituting a clotting factor.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions